Prostate-Specific Antigen Mass and Free Prostate-Specific Antigen Mass for Predicting the Prostate Volume of Korean Men With Biopsy-Proven Benign Prostatic Hyperplasia

Abstract

PurposeIt has been reported that prostate-specific antigen (PSA) correlates with prostate volume. Recently, some studies have reported that PSA mass (PSA adjusted for plasma volume) is more accurate than PSA at predicting prostate volume. In this study, we analyzed the accuracy of PSA and the related parameters of PSA mass, free PSA (fPSA), and fPSA mass in predicting prostate volume.Materials and MethodsWe retrospectively investigated 658 patients who underwent prostate biopsy from 2006 to 2012 and had a confirmed negative biopsy result. International Prostate Symptom Score (IPSS) questionnaire, PSA, fPSA, and prostate volume were investigated. PSA mass and fPSA mass were calculated by use of established formulas. The association between PSA-related parameters and IPSS and prostate volume was assessed by using Pearson correlation coefficient and receiver operating characteristic curves.ResultsThere was no significant difference between PSA and PSA mass, fPSA, or fPSA mass in predicting prostate volume except in obese patients (p-value of PSA-PSA mass for 40 cm3, 0.54; p-value of fPSA-fPSA mass for 40 cm3, 0.34). fPSA performed significantly better than PSA at predicting prostate volume (p-value for 40 cm3, <0.001). IPSS and the aforementioned PSA-related parameters were not significantly correlated.ConclusionsPSA mass was not a better predictive value than PSA for estimating the prostate volume in Korean men except in obese men. This finding was also applicable to the relationship of fPSA and fPSA mass, which appeared to be more accurate predictors of prostate volume than either PSA or PSA mass.

MRI-Based Radiomics Nomogram for Predicting Prostate Cancer with Gray-Zone Prostate-Specific Antigen Levels to Reduce Unnecessary Biopsies

“…This indicates that 75–88.2% of patients undergo unnecessary needle biopsies and are at risk of complications [ 5 ]. In addition, PSA levels are affected by factors such as the volume of the prostate, inflammation of the prostate, and BMI [ 6 , 7 , 8 , 9 ]. Therefore, prebiopsy prediction of PCa in patients with gray-zone PSA levels is a clinical challenge.…”

Long non‑coding RNAs in prostate tumorigenesis and therapy (Review)

“…According to the literature, almost 240,000 individuals developed PCa in the United States yearly; however, <15% of these patients eventually died; mortality is largely dependent upon PSA testing and reasonable treatment of PCa at an early stage (3)(4)(5)(6). However, serum PSA is not particular to PCa, and levels can be enhanced in benign prostatic hyperplasia (BPH) (7) and prostatitis (8) even after a digital rectal examination. Therefore, the lack of specificity limits its further development.…”

Circulating Long Noncoding RNA as a Potential Target for Prostate Cancer

“…For example, PSA is specific to the prostate but not to prostate cancer. PSA can be elevated in some benign situations, such as prostatic hyperplasia [ 12 ] and prostatitis [ 13 ], and PSA levels can change frequently and inconsistently depending on the patient’s condition. Additionally, serum PSA levels are not specifically correlated with malignancy.…”